NICE Collaborates with Menarini to Evaluate Elacestrant Breast Cancer Treatment

By João L. Carapinha

October 10, 2024

The article from the National Institute for Health and Care Excellence (NICE) titled “NICE ready to work with company to address uncertainty in evidence for elacestrant for advanced breast cancer” highlights crucial details regarding the evaluation and potential use of elacestrant breast cancer therapy. Elacestrant is specifically under review for its effectiveness in treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer with an activating ESR1 mutation, which complicates hormone therapies.

Key Points

Condition and Treatment

– Elacestrant is being considered for treating oestrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation. This particular mutation can cause hormone therapies to stop working, leading to cancer progression.

Mechanism of Action

– As an oestrogen receptor degrader, elacestrant binds to and degrades oestrogen receptors, blocking oestrogen’s ability to bind to breast cancer cells and promote their growth.

Draft Guidance

– NICE has issued draft guidance that does not currently recommend elacestrant for this type of advanced breast cancer due to uncertainty in the evidence. This draft is open for public consultation until 22 October 2024.

Evidence and Uncertainty

– The evidence indicates that elacestrant may improve the time before the breast cancer worsens compared to standard care. However, there is considerable uncertainty surrounding these estimates. NICE has requested further analysis from the company to clarify and address this uncertainty.

Patient Eligibility

– It is estimated that about 1,000 individuals could be eligible for treatment with elacestrant breast cancer therapy.

Use of Severity Modifier

– NICE is examining whether to apply a severity modifier, which would give additional weight to the benefits of medicines based on the severity of the disease. This evaluation will continue at the committee’s next meeting on 12 November 2024.

Company and Stakeholders

– The company involved, Menarini Stemline, is collaborating with NICE to address the uncertainties in the evidence for elacestrant. Various patient, carer, and professional groups are also participating in the consultation process.

Context of Previous Recommendations

– Historically, around three-quarters (76%) of topics that were not initially recommended by NICE at the draft stage ended up receiving a positive recommendation before the final guidance was published. This trend suggests that there remains a potential for elacestrant to be recommended if the uncertainties can be successfully resolved.

Reference url

Recent Posts

Argentina WHO Withdrawal
   

Argentina WHO Withdrawal: President Milei Exits Global Health Alliance Amid COVID-19 Disputes

💡 *What happens when a country decides to withdraw from global health organizations?*
Argentina’s President Javier Milei has made the bold move to withdraw from the WHO, citing significant disagreements over health management during the pandemic. This decision raises questions about national sovereignty, cooperation, and the future of global health initiatives. Dive into the implications of Argentina’s stance and what it means for international health governance.

#SyenzaNews #globalhealth #healthcarepolicy

Gauteng HPV vaccination campaign
      

Gauteng HPV Vaccination Campaign: Protecting Girls Against Cervical Cancer

💉 Ready to protect our future generations from cervical cancer?

The Gauteng HPV vaccination campaign aims to vaccinate grade 5, 6, and 7 girls against the virus that causes most cervical cancers. By leveraging a single-dose regimen, this initiative not only enhances access to life-saving vaccines but also strives to meet ambitious global health targets.

Explore how this campaign is reshaping health outcomes in South Africa and why parental consent is key to its success.

#SyenzaNews #HealthEconomics #HealthcareInnovation #UniversalHealthCoverage

Capvaxive vaccine approval
     

Capvaxive Vaccine Approval

🌍 What if a single vaccine could significantly change the landscape of pneumococcal disease prevention in adults?

The European Medicines Agency has just recommended Merck’s Capvaxive, an innovative 21-valent pneumococcal conjugate vaccine! With robust data from multiple phase 3 trials, this potential approval marks a pivotal step in the fight against invasive Streptococcus pneumoniae infections in the EU. Look into how Capvaxive could enhance public health outcomes and offer extensive serotype coverage.

#SyenzaNews #pharmaceuticals #healthcarepolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.